On the one hand, regorafenib suppressed EMT in cholangiocarcinoma (CCA) cells by inhibiting the activity of yes-associated protein 1 (YAP1) and regulating EMT-related genes, including E-cadherin and SNAIL [252]. Here, YAP1 is linked to cholangiocarcinoma.